Fig. 2: Anti-CSP antibody responses to priming and booster doses of the RTS,S/S01E malaria vaccine by gender and age at the time of vaccination. | npj Vaccines

Fig. 2: Anti-CSP antibody responses to priming and booster doses of the RTS,S/S01E malaria vaccine by gender and age at the time of vaccination.

From: The anti-circumsporozoite antibody response to repeated, seasonal booster doses of the malaria vaccine RTS,S/AS01E

Fig. 2

Anti-CSP antibody titres measured by the GSK ELISA in individual children pre- and post-priming vaccination (2017) and pre and post first (2018), second (2019), third (2020) and fourth (2021) booster seasonal vaccination doses are shown by country. Results from children in the Burkina Faso study are shown in red, children in the Mali study are shown in blue. The top panels show titres of male and female children, and the lower panels show titres of younger and older children (age at first vaccination). CSP circumsporozoite, EU enzyme linked immunosorbent assay unit. Only a few children who had been aged 11 months of age at the time of first vaccination were eligible for vaccination in 2021, having reached the age of five years when they were no longer eligible to receive RTS,S/AS01E or SMC in 2021. Consequently, there were only a few vaccinated children in the randomly selected group of children for the immunology serology sub-study in 2021 who had been 11 months old or older at the time of first vaccination.

Back to article page